Pharma Market Access in 2025:
Geo-Competition, RWE, and the Global Policy Storm
In 2025, pharma market access is no longer just about clinical evidence and pricing. It’s now a geopolitical chessboard—where real-world evidence (RWE), health technology assessment (HTA), and policy shifts like U.S. tariffs are shaping which medicines reach patients and how fast.
Join us at the upcoming WLCUS Summit in Frankfurt, where this complexity is unpacked by international experts, including Professor Fabrizio Gianfrate, one of Europe’s leading voices in health economics.
Real-World Evidence: The New Market Access Currency
In today’s healthcare landscape, RWE has become essential for gaining reimbursement and access. No longer limited to supporting literature reviews or post-marketing studies, RWE now sits at the heart of HTA submissions in the EU, UK, and beyond.
Key talking points include:
- The rise of synthetic control arms in clinical trials
- Using real-time patient registries for payer negotiations
The shift from randomized clinical trials to real-world validation
Global Policy Shockwaves: From Trump Tariffs to EMA Reform
The pharma sector is increasingly exposed to political risk. With Trump-era tariffs being reintroduced and global supply chains under pressure, companies face rising costs and shifting trade barriers.
At the same time:
- The U.S. Inflation Reduction Act has shaken the global drug pricing conversation.
- EMA and EU bodies are tightening the evidentiary requirements for HTA, signaling a shift toward more rigorous access hurdles.
Why This Matters for Pharma Leaders
Whether you are working on market access, RWE, HEOR, or government affairs, this evolving landscape means:
- Evidence must be not only clinically sound, but policy-aligned
- Market entry strategies must account for cross-border pricing shifts
- HTA submissions must now stand up to increased scrutiny from both local and global regulators
This is the kind of complexity we’ll address head-on, at the WLCUS Global RWE & Market Acces Summit 2025.
Don’t Miss Our Expert Talk in Frankfurt
Title: “RWE, HTA & Geo-Competitive Market Access: When U.S. Policy Hits EU Strategy”
Presenter: Professor Fabrizio Gianfrate
Date: 15th October, 2025
Location: Frankfurt, Germany
Join us as Professor Gianfrate explores how evidence, economics, and geopolitics intersect, and what it means for your drug’s success in Europe and beyond.
Ready to Navigate the New Normal?
This is more than a conference. It’s a strategic moment for your team to understand and adapt to the most disruptive forces in global healthcare—before they disrupt your pipeline.